公司名稱: 方達控股公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01521 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | ...

截至发稿，泰格医药(03347.HK)涨6.49%、方达控股(01521.HK)涨6.42%、康龙化成(03759.HK)涨 3.21%。 ...

于2025年9月30日，集团的未经审核综合资产净值约为3.45亿美元。 智通财经APP讯，方达控股(01521)发布公告，集团截至2025年9月30日止九个月的收益约为1.914亿美 元，较2024年同期增加0.2%。集团于截至2025年9月30日止九个月的纯利约为560万美元，较截至2024 年9月30日止九个月的纯利约20万美元大幅增长。经扣除以股份为基础的薪酬开支、并购所得无形资产 摊销及并购相关开支后，集团截至2025年9月30日止九个月的经调整纯利约为1260万美元，较2024年同 期增加32.5%。 ...

Core Insights - The company reported a revenue of approximately $191.4 million for the nine months ending September 30, 2025, representing a 0.2% increase compared to the same period in 2024 [1] - The net profit for the same period was approximately $5.6 million, a significant increase from $200,000 in the previous year [1] - Adjusted net profit, excluding share-based compensation, amortization of acquired intangible assets, and acquisition-related expenses, was approximately $12.6 million, reflecting a 32.5% increase year-over-year [1] - As of September 30, 2025, the company's unaudited consolidated net asset value was approximately $345 million [1]

于2025年9月30日，集团的未经审核综合资产净值约为345.0百万美元。 格隆汇10月28日丨方达控股(01521.HK)公布，集团截至2025年9月30日止九个月的收益约为191.4百万美 元，较2024年同期增加0.2%。集团于截至2025年9月30日止九个月的纯利约为5.6百万美元，较截至2024 年9月30日止九个月的纯利约0.2百万美元大幅增长。经扣除以股份为基础的薪酬开支、并购所得无形资 产摊销及并购相关开支后，集团截至2025年9月30日止九个月的经调整纯利约为12.6百万美元，较2024 年同期增加32.5%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 FRONTAGE HOLDINGS CORPORATION 方達控股公司* （於開曼群島註冊成立的有限公司） 本集團截至2025年9月30日止九個月的收益約為191.4百萬美元，較2024年同期增 加0.2%。本集團於截至2025年9月30日止九個月的純利約為5.6百萬美元，較截至 2024年9月30日止九個月的純利約0.2百萬美元大幅增長。經扣除以股份為基礎的 薪酬開支、併購所得無形資產攤銷及併購相關開支後，本集團截至2025年9月30 日止九個月的經調整純利約為12.6百萬美元，較2024年同期增加32.5%。 於2025年9月30日，本集團的未經審核綜合資產淨值約為345.0百萬美元。 1 本公司股東及潛在投資者務請注意，本公告所載資料乃未經審核，亦未經本公司 核數師或本公司董事會審核委員會審閱。本公司股東及潛在投資者於買賣本公司 股份時務請審慎行事。 承董事會命 方達控股公司* 主席 李松博士 香 ...

Group 1: Cobalt Export Quota in Congo - The Democratic Republic of Congo (DRC) has announced a cobalt export quota, effective from October 16, aimed at strengthening resource sovereignty and signaling a shift from a surplus to a shortage in the cobalt market, leading to a systematic increase in price levels [1] - The DRC's Strategic Mineral Market Regulatory Authority stated that miners will be allowed to export slightly over 18,000 tons of cobalt for the remainder of this year, with annual export limits of 96,600 tons for 2026 and 2027, which is less than half of last year's production [1] - The quota distribution includes major companies such as Luoyang Molybdenum, which received a quota of 31,200 tons (32.3%), exceeding some prior expectations [1] Group 2: Future Cobalt Supply and Demand - Institutions predict a cobalt supply gap in the next two years, with global supply expected to be 290,000 tons in 2024 (DRC 220,000 tons + Indonesia 28,000 tons) against a demand of 185,000 tons, resulting in a surplus of 105,000 tons; by 2026, supply is projected to drop to 180,000 tons (DRC 96,600 tons + Indonesia 40,000 tons) while demand will rise to 200,000 tons, leading to a shortfall of 20,000 tons [2] Group 3: Market Trends and Stock Performance - The Nasdaq China Golden Dragon Index fell by 6.1%, with major U.S. stock indices also experiencing significant declines, indicating a bearish trend in the market [3] - Notable declines were observed in large tech stocks, with companies like Broadcom and Tesla dropping nearly 6% and 5.06% respectively, reflecting broader market challenges [3] Group 4: Rare Earth Prices - Baotou Steel and Northern Rare Earth announced an increase in rare earth concentrate prices for Q4 2025, with a projected 37.13% increase compared to Q3 [7] Group 5: Company Announcements - China Energy Construction signed three new energy EPC contracts worth approximately 27.45 billion USD (about 195.54 billion RMB) with Saudi companies [11] - Smoore International reported a record high quarterly revenue of approximately 4.1968 billion RMB, a year-on-year increase of about 27.2% [12] - Kelun-Biotech's TROP2ADC drug received approval for a new indication, expanding its market potential in treating specific lung cancer cases [13] - Zhaojin Mining reported a net profit of approximately 2.117 billion RMB for the first three quarters of 2025, a year-on-year increase of 140.43% [14]

Major Events - Yuan Da Zhu Gong (02163) plans to apply for bankruptcy reorganization at Changsha Intermediate People's Court [1] - Yi Li Holdings (00076) subsidiary intends to issue blockchain vouchers V76, redeemable for bulk commodities on the platform [1] - Peijia Medical-B (09996): National Medical Products Administration accepts registration application for GeminiOne® transcatheter edge-to-edge repair system [1] - Paggen Biopharmaceutical-B (02565) proposes to grant exclusive license for VISEPEGENATIDE (PB-119) in the Middle East and Africa [1] - Beijing Enterprises Environment Group (00154) bids for Hong Kong I·PARK 2 project [1] - Fangda Holdings (01521) plans to acquire Shanghai Guanhua Medical Technology Co., Ltd. for 270 million yuan to enhance global laboratory service capabilities [1] - Lianzhong (06899) focuses on female user value, driving new entertainment through content [1] - Global New Materials International (06616) increases stake in CQV to 50.75%, strengthening global business collaboration [1] - Qianxin Biotechnology-B (02509): Qianxin's industrialization base successfully passes EU QP audit [1] - China Energy Construction (03996) subsidiary signs three new energy general contracting agreements, totaling approximately 19.554 billion yuan [1] - Yongyi International (01218) plans to sell all issued shares of Zhuoyi to Gaoshan (00616) [1] - Bohai Bank (09668) plans to list high capital-occupying debt assets for sale, with an initial pricing of no less than 48.883 billion yuan [1] - Chuangsheng Holdings (02680) plans to receive a premium of about 6% for full acquisition offer, resuming trading on October 13 [1] - Kelun-Botai Biopharmaceutical (06990): Core product TROP2ADC, Lukan-Satuzi (SAC-TMT) approved by National Medical Products Administration for third indication, treating EGFR mutation non-small cell lung cancer after EGFR-TKI progression [1] Operating Performance - Zhaojin Mining (01818) reports net profit of approximately 2.117 billion yuan for the first three quarters, a year-on-year increase of 140.43% [2] - Sunny Optical Technology (02382): September mobile phone camera module shipments reach 48.524 million units, a month-on-month increase of 15.3% and a year-on-year increase of 32% [2] - Yuexiu Property (00123) reports cumulative contract sales of approximately 79.812 billion yuan for the first nine months, a year-on-year increase of about 2.8% [2] - Qiu Tai Technology (01478) reports September camera module sales of 46.654 million units, a month-on-month decrease of 7.6% but a year-on-year increase of 45.1% [2]

Group 1 - The acquisition involves a total consideration of RMB 270 million, with the target company becoming a wholly-owned subsidiary of the acquiring company after the transaction [1] - The target company specializes in clinical trial technology services and related laboratory services, enhancing the acquiring company's global laboratory service capabilities and influence in China [2] - The acquisition is expected to strengthen the acquiring company's position as a trusted partner in the clinical research industry by expanding its center laboratory services in China and the Asia-Pacific region [2] Group 2 - The target group has extensive experience supporting over 1,500 clinical trials across multiple therapeutic areas and is known for its compliance with Good Clinical Practice (GCP) [2] - The acquisition will enhance the ability to provide high-quality one-stop services to pharmaceutical companies, contract research organizations, and research institutions [2] - The target company's successful track record includes contributions to the successful launch of 35 new drugs and support for regulatory audits [2]

Core Viewpoint - The acquisition of 100% equity in Shanghai Guanhua Medical Technology Co., Ltd. by Fangda Holdings aims to enhance the group's global laboratory service capabilities and strengthen its influence in China [1][2] Group 1: Acquisition Details - Fangda Holdings' wholly-owned subsidiary, Fangda Shanghai, plans to acquire Shanghai Guanhua Medical Technology for a total consideration of RMB 270 million [1] - The target company specializes in clinical trial technology services, related services, and laboratory services [1] Group 2: Strategic Objectives - The acquisition is intended to expand the group's central laboratory services in China and enhance its influence in the Asia-Pacific region [1] - The target group has extensive experience supporting over 1,500 clinical trials across multiple therapeutic areas, known for its compliance with Good Clinical Practice (GCP) and internationally recognized services [1][2] Group 3: Synergy and Market Position - The target group's strong track record, including its role in the successful launch of 35 new drugs and support for regulatory audits, complements the existing expertise of the group [2] - The acquisition will enhance the group's ability to provide high-quality one-stop services to pharmaceutical companies, contract research organizations, and research institutions, further solidifying its position as a trusted partner in the clinical research industry [2]